High-sensitivity cardiac troponin i and t for cardiovascular risk stratification in adults with diabetes

Olive Tang; Kunihiro Matsushita; Josef Coresh; Chiadi Ndumele; John W. McEvoy; A. Richey Sharrett; Ron Hoogeveen; Christie M. Ballantyne; Elizabeth Selvin

doi:10.2337/dc20-1312

High-sensitivity cardiac troponin i and t for cardiovascular risk stratification in adults with diabetes

Olive Tang, Kunihiro Matsushita, Josef Coresh, Chiadi Ndumele, John W. McEvoy, A. Richey Sharrett, Ron Hoogeveen, Christie M. Ballantyne, Elizabeth Selvin

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	e144-e146
Journal	Diabetes care
Volume	43
Issue number	10
DOIs	https://doi.org/10.2337/dc20-1312
State	Published - Oct 2020

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialized Nursing

Access to Document

10.2337/dc20-1312

Cite this

@article{1348b4ea1ada4a9baa992cee8ef83290,

title = "High-sensitivity cardiac troponin i and t for cardiovascular risk stratification in adults with diabetes",

author = "Olive Tang and Kunihiro Matsushita and Josef Coresh and Chiadi Ndumele and McEvoy, {John W.} and Sharrett, {A. Richey} and Ron Hoogeveen and Ballantyne, {Christie M.} and Elizabeth Selvin",

note = "Funding Information: The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Duality of Interest. C.M.B. and R.H. are coinventors on a provisional patent (patent no. 61721475) entitled Biomarkers to Improve Prediction of Heart Failure Risk filed by Roche Diagnostics and Baylor College of Medicine on their behalf. C.M.B. receives grant/research support from Abbott Diagnostics and Roche Diagnostics as well as the NIH and is a consultant for Abbott Diagnostics and Roche Diagnostics. R.H. has received grant support and consulting fees from Denka Seiken outside the submitted work. E.S. has served on the advisory board for Roche Diagnostics. K.M. has received nonfinancial support from Roche Diagnostics outside of this work. No other potential conflicts of interest relevant to this article were reported. Author Contributions. O.T. and E.S. designed the study and drafted the manuscript. O.T. conducted the analyses. O.T., K.M., J.C., C.N., J.W.M., A.R.S., R.H., C.M.B., and E.S. provided data interpretation and meaningful contributions to the revision of the manuscript. O.T. and E.S. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Prior Presentation. Parts of this study were presented in abstract form at the 79th Scientific Sessions of the American Diabetes Association, San Francisco, CA, 7–11 June 2019. Funding Information: The authors thank the staff and participants of the ARIC study for their indispensable contributions. Reagents for the hs-cTnT assay were donated by Roche Diagnos-tics, and reagents for the hs-cTnI assay were donated by Abbott Diagnostics. Funding. The ARIC study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), and the Department of Health and Human Services (under contract nos. HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, and HHSN268201700005I). O.T. is supported by NIH/ National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant F30DK120160. E.S. is supported by NIH/NIDDK grants K24DK106414 and R01DK089174. C.M.B. is supported by NIH/NHLBI R01HL134320. The content of this work is solely the re-sponsibility of the authors and does not neces-sarily represent the official views of the NIH. Funding Information: Acknowledgments. The authors thank the staff and participants of the ARIC study for their indispensable contributions. Reagents for the hs-cTnT assay were donated by Roche Diagnostics, and reagents for the hs-cTnI assay were donated by Abbott Diagnostics. Funding. The ARIC study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), and the Department of Health and Human Services (under contract nos. HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, and HHSN268201700005I). O.T. is supported by NIH/ National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant F30DK120160. E.S. is supported by NIH/NIDDK grants K24DK106414 and R01DK089174. C.M.B. is supported by NIH/NHLBI R01HL134320.",

year = "2020",

month = oct,

doi = "10.2337/dc20-1312",

language = "English (US)",

volume = "43",

pages = "e144--e146",

journal = "Diabetes care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

number = "10",

}

TY - JOUR

T1 - High-sensitivity cardiac troponin i and t for cardiovascular risk stratification in adults with diabetes

AU - Tang, Olive

AU - Matsushita, Kunihiro

AU - Coresh, Josef

AU - Ndumele, Chiadi

AU - McEvoy, John W.

AU - Sharrett, A. Richey

AU - Hoogeveen, Ron

AU - Ballantyne, Christie M.

AU - Selvin, Elizabeth

N1 - Funding Information: The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Duality of Interest. C.M.B. and R.H. are coinventors on a provisional patent (patent no. 61721475) entitled Biomarkers to Improve Prediction of Heart Failure Risk filed by Roche Diagnostics and Baylor College of Medicine on their behalf. C.M.B. receives grant/research support from Abbott Diagnostics and Roche Diagnostics as well as the NIH and is a consultant for Abbott Diagnostics and Roche Diagnostics. R.H. has received grant support and consulting fees from Denka Seiken outside the submitted work. E.S. has served on the advisory board for Roche Diagnostics. K.M. has received nonfinancial support from Roche Diagnostics outside of this work. No other potential conflicts of interest relevant to this article were reported. Author Contributions. O.T. and E.S. designed the study and drafted the manuscript. O.T. conducted the analyses. O.T., K.M., J.C., C.N., J.W.M., A.R.S., R.H., C.M.B., and E.S. provided data interpretation and meaningful contributions to the revision of the manuscript. O.T. and E.S. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Prior Presentation. Parts of this study were presented in abstract form at the 79th Scientific Sessions of the American Diabetes Association, San Francisco, CA, 7–11 June 2019. Funding Information: The authors thank the staff and participants of the ARIC study for their indispensable contributions. Reagents for the hs-cTnT assay were donated by Roche Diagnos-tics, and reagents for the hs-cTnI assay were donated by Abbott Diagnostics. Funding. The ARIC study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), and the Department of Health and Human Services (under contract nos. HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, and HHSN268201700005I). O.T. is supported by NIH/ National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant F30DK120160. E.S. is supported by NIH/NIDDK grants K24DK106414 and R01DK089174. C.M.B. is supported by NIH/NHLBI R01HL134320. The content of this work is solely the re-sponsibility of the authors and does not neces-sarily represent the official views of the NIH. Funding Information: Acknowledgments. The authors thank the staff and participants of the ARIC study for their indispensable contributions. Reagents for the hs-cTnT assay were donated by Roche Diagnostics, and reagents for the hs-cTnI assay were donated by Abbott Diagnostics. Funding. The ARIC study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), and the Department of Health and Human Services (under contract nos. HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, and HHSN268201700005I). O.T. is supported by NIH/ National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant F30DK120160. E.S. is supported by NIH/NIDDK grants K24DK106414 and R01DK089174. C.M.B. is supported by NIH/NHLBI R01HL134320.

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85091470224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091470224&partnerID=8YFLogxK

U2 - 10.2337/dc20-1312

DO - 10.2337/dc20-1312

M3 - Article

C2 - 32788284

AN - SCOPUS:85091470224

SN - 0149-5992

VL - 43

SP - e144-e146

JO - Diabetes care

JF - Diabetes care

IS - 10

ER -

High-sensitivity cardiac troponin i and t for cardiovascular risk stratification in adults with diabetes

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this